Global revenue of anti-diabetic products 2008-2018

This statistic displays the global pharmaceutical spending on anti-diabetic products from 2008 to 2018. In 2008, the revenue stood at some 27 billion U.S. dollars. Since then, this figure increased to almost 79 billion U.S. dollars in 2018. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.